I bet the 3 drug combo is priced higher so it ends up being comparable in price to 12 weeks of eplcusa. GILD gets a premium to treat a prior failure - entirely fair - and they can then promote the triple for 8 weeks in naives and get docs used to prescribing it in this setting in advance of potential short duration competition down the road The downside of failing tx is large so i can see in that scenario some docs/pts opting for another month of tx for some incremental benefit (especially if it is more than 3% in certain subsets once details of the study are made public)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.